Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis

Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis

Ernst HundDepartment of Neurology, University of Heidelberg, Heidelberg, GermanyAbstract: Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a fatal clinical disorder characterized by extracellular deposition of abnormal fibrils derived from misfolded, normally soluble transthyretin (TTR) mo...

Full description

Bibliographic Details
Main Author:	Hund E
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-06-01
Series:	The Application of Clinical Genetics
Online Access:	http://www.dovepress.com/familial-amyloidotic-polyneuropathy-current-and-emerging-treatment-opt-a10151

Similar Items

Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients
by: Márcia Cavalcanti de Campos Queiroz, et al.
Published: (2015-11-01)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
by: Jennifer Kollmer, et al.
Published: (2020-05-01)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
by: Vélez-Santamaría V, et al.
Published: (2022-12-01)

Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells
by: Kaori Isono, et al.
Published: (2014-03-01)

MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy
by: Diana Martins, et al.
Published: (2017-10-01)

Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
by: S. S. Nikitin, et al.
Published: (2021-12-01)

Ocular Manifestations in a Chinese Pedigree of Familial Amyloidotic Polyneuropathy Carrying the Transthyretin Mutation c.401A>G (p.Tyr134Cys)
by: Xiaonan Zhuang, et al.
Published: (2022-05-01)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
by: Dixon S, et al.
Published: (2023-11-01)

Late-onset familial amyloidosis polyneuropathy associated with c.186G>C in transthyretin
by: Eugenia Conti, et al.
Published: (2024-03-01)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
by: Ivan Urits, et al.
Published: (2020-08-01)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
by: Luigetti M, et al.
Published: (2020-02-01)

Familial amyloidotic polyneuropathy with muscle, vitreous, leptomeningeal, and cardiac involvement: Phenotypic, pathological, and MRI description
by: Prashantha D, et al.
Published: (2010-01-01)

Transthyretin amyloidoses of familial amyloidotic polyneuropathy as a paradigm for the genetic control of spontaneous generation of infectious amyloids by patterned configurational change in host precursors in Creutzfeldt-Jacob disease.
by: D C Gajdusek
Published: (1991-12-01)

Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activity.
by: Gonçalo da Costa, et al.
Published: (2011-01-01)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
by: Volha Skrahina, et al.
Published: (2021-01-01)

Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis
by: Christopher Robinson, et al.
Published: (2023-01-01)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
by: Laura Obici, et al.
Published: (2023-07-01)

A case of familial amyloidotic polyneuropathy with a rare Phe33Leu mutation in the TTR gene
by: Chih-Hao Chen, et al.
Published: (2014-08-01)

Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy
by: Chieh-Chang Chen, et al.
Published: (2024-03-01)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
by: Aaron Yarlas, et al.
Published: (2023-03-01)

Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report
by: Robin Jason, et al.
Published: (2008-02-01)

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
by: Maria do Carmo Vilas-Boas, et al.
Published: (2020-11-01)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
by: Kathleen W. Zhang, MD, et al.
Published: (2019-06-01)

Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy
by: Marcus Vinicius Pinto, et al.

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis
by: Maria do Carmo Vilas-Boas, et al.
Published: (2022-08-01)

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
by: Mónica Inês, et al.
Published: (2020-03-01)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
by: Huizhen Zou, et al.
Published: (2023-09-01)

The progress in diagnosis and treatment of transthyretin amyloid polyneuropathy
by: ZHU Xi⁃ying, et al.
Published: (2021-06-01)

TRANSTHYRETIN POLYNEUROPATHY (CLINICAL CASE)
by: Наталья Викторовна Коробкова, et al.
Published: (2023-08-01)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
by: David Rintell, et al.
Published: (2021-02-01)

Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort
by: Nath Pasutharnchat, et al.
Published: (2021-05-01)

Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments
by: Arman Çakar, et al.
Published: (2017-09-01)

Nerve Ultrasound Comparison Between Transthyretin Familial Amyloid Polyneuropathy and Chronic Inflammatory Demyelinating Polyneuropathy
by: Kang Du, et al.
Published: (2021-02-01)

Management of transthyretin amyloidosis
by: Adalgisa Condoluci, et al.
Published: (2021-10-01)

Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01)

Transthyretin cardiac amyloidosis: an update on diagnosis and treatment
by: Hiroyuki Yamamoto, et al.
Published: (2019-12-01)

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
by: Faruk Uğur Doğan, et al.
Published: (2019-03-01)

Erratum to: Management of transthyretin amyloidosis
by: Swiss Medical Weekly
Published: (2021-11-01)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
by: Giampaolo Merlini, et al.
Published: (2020-02-01)

Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
by: Maike F. Dohrn, et al.
Published: (2021-11-01)